Mechanism and Research Interest

Primary Biological Pathway: VPAC Receptor Signalling

VIP exerts its physiological effects by binding to the Class B G-protein coupled receptors, VPAC1 and VPAC2.

The primary research focus involves the activation of the adenylate cyclase pathway, leading to an increase in intracellular cyclic adenosine monophosphate (cAMP) and the subsequent activation of Protein Kinase A (PKA). In laboratory models, this cascade is observed to induce broad-spectrum smooth muscle relaxation (bronchodilation and vasodilation) and is currently being mapped for its role in modulating synaptic transmission in the central nervous system.

Secondary Research Finding: Immunomodulation and Anti-Inflammatory Action

A significant volume of contemporary research focuses on VIP’s capacity to regulate the immune response. VIP is known to inhibit the production of pro-inflammatory cytokines (such as TNF-$\alpha$, IL-6, and IL-12) while stimulating the production of anti-inflammatory cytokines (IL-10). Researchers are utilising this 10mg presentation to study the peptide’s ability to shift the T-helper cell balance from a Th1 (inflammatory) to a Th2 (protective) profile, offering a potential mechanism for investigation in autoimmune models such as rheumatoid arthritis and inflammatory bowel disease.

Tertiary Research Finding: Pulmonary Haemodynamics

VIP is extensively studied for its potent vasodilatory effects on the pulmonary vasculature. By relaxing the smooth muscle of the pulmonary arteries, VIP decreases pulmonary vascular resistance. Research models of pulmonary hypertension utilise VIP to evaluate the reversibility of vascular remodelling and to assess improvements in right ventricular ejection fraction. The 10mg pen allows for the sustained administration required to observe these haemodynamic changes over time.

Long-term Genomic and Safety Observations

Current longitudinal studies are examining the role of VIP in the maintenance of the circadian clock. VIP-expressing neurons in the SCN are essential for synchronising cellular rhythms. Genomic analysis in “knockout” models suggests that VIP deficiency leads to profound circadian disruption. Researchers are using exogenous VIP to determine if supplementation can restore transcriptional rhythmicity in peripheral tissues, a key area of interest for metabolic health and ageing research.

Product Specifications

• Purity: Validated at >98+% via High-Performance Liquid Chromatography (HPLC). VIP is susceptible to oxidation (particularly at the Methionine residue); our manufacturing process utilises an inert atmosphere to prevent degradation during synthesis.

• Appearance: The 3ml pen contains a clear, sterile liquid solution.

• Precision: The pen device ensures accurate volumetric delivery, which is critical given the picomolar affinity of VIP for its receptors.

• Storage: The peptide must be maintained at $2^{\circ}C$ to $8^{\circ}C$.

Storage and Shipping Guidelines

Refrigeration and Shelf Life

The VIP 10mg Pen contains a highly sensitive peptide structure. It must be refrigerated ($2^{\circ}C$ to $8^{\circ}C$) immediately upon receipt. The shelf life is 12 months in the sealed state. Once the pen is used, the risk of enzymatic degradation or oxidation increases; it is best practice to complete the experimental protocol within 21 days.

Shipping Stability

We utilise advanced thermal packaging for VIP shipments. The lyophilised-reconstituted hybrid solution is stable for up to 48 hours at ambient temperatures. However, due to the specific sensitivity of the VIP amino acid sequence to heat, we strongly recommend selecting the fastest shipping option available.

Freezing Warning

Strictly avoid freezing. Freezing the solution can induce structural changes that impair receptor binding affinity. Furthermore, the expansion of the liquid can damage the pen’s internal mechanism. A frozen pen should be discarded as the bioavailability cannot be guaranteed.

Why Choose the Peptide Pro 3ml Pen Format?

Research involving VIP has historically been hampered by the peptide’s short half-life and instability in solution. Traditional vial reconstitution exposes the peptide to atmospheric oxygen and potential contaminants, leading to rapid loss of potency.

The VIP 10mg Pen mitigates these risks by providing a closed, sterile system. The bacteriostatic environment preserves the integrity of the peptide sequence, ensuring that the concentration injected on Day 1 is identical to Day 21. This consistency is paramount for immunomodulation studies where dosage precision correlates directly with cytokine inhibition rates.

For researchers exploring related anti-inflammatory or gut-health peptides, we recommend examining:

• BPC-157 10mg: (For comparative studies on gastric mucosal protection).

• TB-500 10mg: (For comparative studies on tissue repair and inflammation).

Disclaimer

This product is strictly for Research Use Only (RUO). It is not intended for human consumption, injection, therapeutic use (such as for asthma or erectile dysfunction), or diagnostic procedures. The information provided is for educational and scientific reference only. Purchase is restricted to verified research institutions. Any evidence of intended misuse for human application will result in immediate order cancellation and blacklisting, in compliance with UK research chemical regulations.